Commerce Bank raised its position in Impax Laboratories, Inc.
According to the Recommendation Trends of the stock polled by Finviz, the company has a consensus recommendation of 2.9 out of the scale from 1 to 5 where 1 stands for Buy and 5 means Sell. Commerce Bank's holdings in Impax Laboratories were worth $145,000 as of its most recent SEC filing.
A number of institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in shares of Impax Laboratories by 12.2% in the fourth quarter. Norges Bank bought a new position in shares of Impax Laboratories during the fourth quarter worth about $16,669,000. MA raised its stake in shares of Impax Laboratories by 1.2% in the first quarter. MA now owns 14,414 shares of the specialty pharmaceutical company's stock valued at $182,000 after buying an additional 171 shares during the period. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company's stock valued at $79,080,000 after buying an additional 276,765 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Impax Laboratories by 4.6% in the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company's stock valued at $102,000 after buying an additional 150 shares during the period. Institutional investors own 84.03% of the company's stock.
Shares of Impax Laboratories (NASDAQ IPXL) traded up 1.986% during mid-day trading on Monday, reaching $14.125. The shares are at this time trading -5.33% less than its SMA 50 and -12.29% under its SMA 200. Impax Laboratories, Inc. has a one year low of $7.75 and a one year high of $32.52. On August 15, 2016 the stock rating was changed to a "Outperform" in a report from Northland Securities which is up from the previous "Market Perform" rating.
Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Wednesday, May 10th. In contrast, the average volume was 2.12 million shares. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.12 by $0.01. Impax Laboratories had a positive return on equity of 7.71% and a negative net margin of 71.50%. IPXL generated revenue of $272.9 Million in the same quarter, one year ago. During the same quarter in the prior year, the business earned $0.43 EPS. The stock's 50-day moving average is $15.22 and its 200 day moving average is $13.24.
ILLEGAL ACTIVITY NOTICE: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of worldwide trademark and copyright laws. The correct version of this story can be accessed at https://transcriptdaily.com/2017/06/19/impax-laboratories-inc-ipxl-stock-rating-reaffirmed-by-janney-montgomery-scott-updated.html.
A number of analysts have recently weighed in on IPXL shares. Zacks Investment Research upgraded Impax Laboratories from a "strong sell" rating to a "hold" rating in a research report on Monday, May 8th.
A look at some of the inputs to technical analysis model shows how Impax Laboratories, Inc. current price compares to its recent moving averages. Cantor Fitzgerald initiated coverage on Impax Laboratories in a report on Friday. Deutsche Bank AG raised Impax Laboratories from a "hold" rating to a "buy" rating and set a $11.00 price objective on the stock in a research note on Wednesday, March 8th. Guggenheim reissued a "buy" rating and issued a $20.00 target price on shares of Impax Laboratories in a research note on Monday, March 27th. According to Thomson Reuters, sell-side analysts are predicting a consensus target price of $16.09 on company stock. Susquehanna Bancshares Inc cut Impax Laboratories from a "positive" rating to a "neutral" rating and dropped their price objective for the company from $18.00 to $10.00 in a report on Wednesday, March 8th. The Company operates in two segments, which include Impax Generics and Impax Specialty Pharma.